Clinical Trials Browser

monalizumab × Clear all

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05903092 2026-04-07

MOZART

Phase 2 Suspended

Small Cell Lung Carcinoma

NCT06152523 2026-04-06

MONAMI

Phase 2 Withdrawn

Neoplasms

NCT06769126 2026-03-30

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04590963 2026-03-13

INTERLINK-1

Phase 3 Active not recruiting

370 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT05061550 2026-03-11

NeoCOAST-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05221840 2026-01-27

PACIFIC-9

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07146230 2025-12-24

SPRINT 2

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT03801902 2025-09-23

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Phase 1 Completed

26 enrolled 17 charts

Lung Neoplasms

NCT02671435 2025-07-22

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Phase 1/2 Active not recruiting

383 enrolled 48 charts

Neoplasm Metastasis

NCT06892223 2025-03-24

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Phase 2 Recruiting

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04307329 2024-10-22

MIMOSA

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03822351 2024-10-08

COAST

Phase 2 Completed

189 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03833440 2024-05-03

PIONeeR

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT02643550 2023-05-12

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1/2 Completed

Head and Neck Neoplasms

NCT04333914 2022-09-30

IMMUNONCOVID

Phase 2 Completed

COVID-19, Infections, Neoplasms

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

84 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04145193 2020-09-21

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT02557516 2019-12-17

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

Phase 1/2 Terminated

22 enrolled 16 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02921685 2018-09-19

PIRAT

Phase 1 Unknown

Other hematologic neoplasm

Hematologic Neoplasms

NCT03307941 2017-12-19

ARTEMIS-Eso

Phase 1/2 Withdrawn

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma